||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Synairgen Share Discussion Threads
Showing 476 to 500 of 500 messages
|How low are the MMs gonna force this? it is already undervalued....|
|Nobby, yes I bought a few more on Wednesday.|
|I added a few more at 22p.
I'm still well up on SNG from the time I first started buying between 18p and 25p in 2011(I sold a lot at 54p anf bought back lower).
I've just been looking back at my old posts from then - happy times indeed.
I was encouraged to see Griffiths buying
As the FT commented last year.
And as one market sage observes: “You wouldn’t want to be a buyer if Woodford or Griffiths were sellers.”|
As well as being at the Proactive presentations on Thursday last week, I was also at the Biotech conference on Tuesday. I saw Richard Marsden present and was quite impressed. Luckily I did nothing in the short term but I have to say the fall looks overdone as all is most definitely not lost for the product.
Are you looking to buy at this level?
|Just watched the proactive video (post #420) which was shot immediately following the news that AZ will be terminated their study early.
Richard Marsden sounds remarkably bullish and points out that there are potential upsides with respect to timings and data analysis. A bit of director buying now would help settle the nerves (I assume they are not currently in a closed period).|
AstraZeneca keeps hanging out the “for sale” sign. While diabetes care is an expanding market in many emerging markets like China, this latest deal reflects the British pharma’s strategy of shifting toward core therapeutic areas, such as oncology and respiratory, and selling off non-core assets.|
Griffiths just added another 330k.|
|I think if you went for ER patients, you would still only enrol them onto the trial if the assignable cause for the exacerbation was a respiratory tract infection (I believe RT infections are the main cause for exacerbations in asthma and COPD so most of the asthma patients admitted to ER should meet with that required criteria).
There is one potential problem with this approach (which Verona will have in their trial too), there are a lot of fatalities in ER rooms for respiratory patients, but perhaps mortality could become one of the secondary end points.|
|Maybe youre right about going for a possible "non flu" route.
I was interested you said earlier they may have picked a low bar for entry because it didn't seem that way to me reading the trial req for volunteers.
To have had at least two documented severe asthma exacerbations within the last 24 months that were suspected by the patient to have been caused by a common cold or flu and To have had at least one documented severe asthma exacerbation within the last 12 months that was suspected by the patient to have been caused by a common cold or flu
I think they just got unlucky with the mildness of the flu symptoms this past year.I know I'm northern hemisphere but I can't recall having a bad case of flu for at least 2 years.
For something that is so well tolerated and kills Swine flu/Bird flu 95% stone dead in the lab it seems a very unfortunate result.
(PS I see Finncap havent changed their 137p target today)|
|Indeed, EV value must be less than total amount invested so far, so on that basis alone they must look cheap to someone like AZ.
I've just been thinking about how they could have designed the study to give a better chance of a successful outcome.
Perhaps it would have been better to go for an emergency room setting where all admitted asthma patients would have a severe exacerbation (otherwise they would not be there).
Verona Pharma have opted for that sort of route for their late phase II /phase III clinicals on RPL554 for COPD.|
|EV now just 15m$ which is far too low for what they've already achieved.
If AZN is really interested in progressing its respiratory business SNG would seem like an ideal add on .
For example AZN's treatment for IPF (tralokinumab) has been dropped (though it may be OK for asthma) so a collaboration with SNG /PXS on its loxl research would make much sense.|
|>>>>Wookie, they are all listed in the link above|
|what are the secondary outcomes?|
|It sounds as if the number of infections is not the problem, it's the lack of severity in the symptoms. This is presumably a function of setting the bar too low for entry on to the trial and a mild cold and flu season.
What is really required is a really nasty strain to come along (Swine flu or Bird flu?) which effects the lower RT rather than the upper RT, (i.e. more cough than cold).
It's worth just revisiting the outline protocol
AZ certainly commissioned enough centres in enough countries.
On the positive side, they have a very large number of secondary outcomes to look at and with which to conduct the revised analysis.|
|Its always been a stock which moves on very little volume .
Works both ways of course.!|
|Wow 30% drop on only 150,000 sales lol|
|Was always a risk they wouldnt get enough patients to have a statistically significant result at the end of thr trial. It seems the flu season over the past year has been quite benign worldwide and I'm sure thats had some effect on the level of "bad exacerbations".
I'd doubt very much if AZN would drop the product at this stage.|
|Today's news is good for patients on the trial (less exacerbations than expected for all participants on the trial) but frustrating for Synairgen and Astra Zeneca.
I suspect the market reaction will be a substantial mark down at the open as this must add to the uncertainty regarding Astra Zeneca's ultimate decision whether or not to go ahead, but at least we know now that the decision will be taken before end of Q1/17. Although not stated in the RNS it wouldn't surprise me if we hear about their decision in the current quarter.|
|ok so nothing wrong with the product just not enough patients got colds! Is that how everyone else reads it?!|
|Pharmaceutical giant AstraZeneca (AZN) will divest its rights to market Rhinocort Aqua outside of the United States for $330 million (£265.1 million).
The company said that the deal would let it focus its respiratory arm on Asthma and COPD treatments. The shares climbed 60p to 5,086p.
|Yes / thanks a lot timbo.|
|Thanks for the update Timbo. Much appreciated.|
|Synairgen were at the Biotech Capital Conference earlier this week in London, with Richard Marsden (RM) giving the Synairgen presentation. The slide set and video should be available on line sometime next week.
We have seen much of the presentation before, especially the slides concerning the tie up with Astra Zeneca and the ongoing clinical study using inhaled beta interferon to treat exacerbations in Asthma. However, I think there was some new information presented on the IPF project and other pipeline developments (see selected slides below), so I will just concentrate on those aspects of RM’s talk:
I asked a couple of questions during Q&As about slide 16 (see below) which I don’t recall seeing before. The positive control shown on the graph is BAPN (beta-Aminopropionitrile) a small naturally occurring molecule that is found in Sweet-peas
It is a non-selective LOXL inhibitor, i.e. it inhibits LOXL1, 2 3 etc which means it is not suitable for IPF due to probable unacceptable side effects, however it has found uses in veterinary medicine for the treatment of tendonitis in race horses.
During the coffee break I had the opportunity to ask a number of other questions regarding the LOXL2 program, the ongoing Asthma clinical and the search for additions to the pipeline, brief details are summarised below:
Synairgen are still looking at several candidate molecules in the LOXL2 program, but the short list is getting smaller and they are still on track to enter the clinic in 2017. All candidates are small (non-peptide) molecules that should be suitable for oral dosing.
The ongoing beta interferon asthma study is proceeding according to plan. AZ are just finishing the Southern Hemisphere studies and then it will be back up to the Northern Hemisphere for the winter cold season for what is hoped will be the final patients. If insufficient patients have completed by the end of the Northern Hemisphere cold season they will do another Southern Hemisphere cold season, but either way the study should report in 2017. AZ are 100% in control and Synairgen play no part in the clinical operations. RM does not expect to get a “quick look see” during analysis of the results and only expects to see the results when AZ issue their own internal final clinical report. Synairgen are likely to announce the outcome as soon as they receive the results (i.e. there is not likely to be any significant delay).
The search for additional pipeline drugs continues. Synairgen may be looking at two or three candidates at any one time, the screening involves both desk work and laboratory work utilising the Southampton cell bank. They have been close to selecting one or two additional candidates, but so far none of them have met all of the required criteria (which includes a requirement to have billion dollar sales potential).
Selected Slides from Synairgen Presentation (5th October 2016)